Anti-oestrogenic chemoprevention of breast cancer: the need to progressPOWLES, Trevor J.European journal of cancer (1990). 2003, Vol 39, Num 5, pp 572-579, issn 0959-8049, 8 p.Article

Chemoprevention options for BRCA1 and BRCA2 mutation carriersEELES, Rosalind A; POWLES, Trevor J.Journal of clinical oncology. 2000, Vol 18, Num 21, pp 93s-99s, issn 0732-183X, SUPArticle

Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancerMCCLOSKEY, Eugene; PATERSON, Alexander; KANIS, John et al.European journal of cancer (1990). 2010, Vol 46, Num 3, pp 558-565, issn 0959-8049, 8 p.Article

Extended safety profile of oral clodronate after long-term use in primary breast cancer patientsATULA, Sari; POWLES, Trevor; PATERSON, Alexander et al.Drug safety. 2003, Vol 26, Num 9, pp 661-671, issn 0114-5916, 11 p.Article

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataCUZICK, Jack; SESTAK, Ivana; MERSHON, John et al.Lancet (British edition). 2013, Vol 381, Num 9880, pp 1827-1834, issn 0140-6736, 8 p.Article

Lasofoxifene in Postmenopausal Women with OsteoporosisCUMMINGS, Steven R; ENSRUD, Kristine; ARMSTRONG, Roisin A et al.The New England journal of medicine. 2010, Vol 362, Num 8, pp 686-696, issn 0028-4793, 11 p.Article

Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic WomenLACROIX, Andrea Z; POWLES, Trevor; ENSRUD, Kristine E et al.Journal of the National Cancer Institute. 2010, Vol 102, Num 22, pp 1706-1715, issn 0027-8874, 10 p.Article

Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging : Initial clinical resultsPADHANI, Anwar R; HAYES, Carmel; ASSERSOHN, Laura et al.Radiology. 2006, Vol 239, Num 2, pp 361-374, issn 0033-8419, 14 p.Article

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistanceCLEATOR, Susan; TSIMELZON, Anna; CHANG, Jenny C et al.Breast cancer research and treatment. 2006, Vol 95, Num 3, pp 229-233, issn 0167-6806, 5 p.Article

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancerPOWLES, Trevor; PATERSON, Sandy; PAJUNEN, Marjo et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3219-3224, issn 0732-183XArticle

Arzoxifene for Prevention of Fractures and Invasive Breast Cancer in Postmenopausal WomenCUMMINGS, Steven R; MCCLUNG, Michael; CHRISTIANSEN, Claus et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 2, pp 397-404, issn 0884-0431, 8 p.Article

Oral bisphosphonates as adjuvant therapy for operable breast cancerPOWLES, Trevor; MCCROSKEY, Eugene; PATERSON, Alexander et al.Clinical cancer research. 2006, Vol 12, Num 20, issn 1078-0432, 6301s-6304s, 2Conference Paper

Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trialPOWLES, Trevor J; ASHLEY, Sue; TIDY, Alwynne et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 4, pp 283-290, issn 0027-8874, 8 p.Article

The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analysesASSERSOHN, Laura; GANGI, Lisa; YINGDONG ZHAO et al.Clinical cancer research. 2002, Vol 8, Num 3, pp 794-801, issn 1078-0432Article

Tamoxifen for the prevention of breast cancer : Psychosocial impact on women participating in two randomized controlled trialsFALLOWFIELD, Lesley; FLEISSIG, Anne; EDWARDS, Rob et al.Journal of clinical oncology. 2001, Vol 19, Num 7, pp 1885-1892, issn 0732-183XArticle

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifenePOWLES, Trevor J; DIEM, Susan J; CUMMINGS, Steven R et al.Breast cancer research and treatment. 2012, Vol 134, Num 1, pp 299-306, issn 0167-6806, 8 p.Article

Continuing outcomes Relevant to evista: Breast Cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneMARTINO, Silvana; CAULEY, Jane A; BARRETT-CONNOR, Elizabeth et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 23, pp 1751-1761, issn 0027-8874, 11 p.Article

Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoALOPEZ, Miguel; LELLIOTT, Christopher J; O'RAHILLY, Stephen et al.Diabetes (New York, NY). 2006, Vol 55, Num 5, pp 1327-1336, issn 0012-1797, 10 p.Article

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trialCAULEY, Jane A; NORTON, Larry; STEPAN, Jan J et al.Breast cancer research and treatment. 2001, Vol 65, Num 2, pp 125-134, issn 0167-6806Article

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002WINER, Eric P; HUDIS, Clifford; BRAUN, Susan et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3317-3327, issn 0732-183XArticle

American society of clinical oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant settingWINER, Eric P; HUDIS, Clifford; GOLDSTEIN, Lori J et al.Journal of clinical oncology. 2003, Vol 21, Num 13, pp 2597-2599, issn 0732-183X, 3 p.Article

Advances in treating metastatic bone cancer : Summary statement for the first cambridge conferenceLIPTON, Allan; BERENSON, James R; GUISE, Theresa A et al.Clinical cancer research. 2006, Vol 12, Num 20, issn 1078-0432, 6209s-6212s, 2Conference Paper

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004WINER, Eric P; HUDIS, Clifford; COBLEIGH, Melody A et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 619-629, issn 0732-183X, 11 p.Article